Kim-Hien T. Dao, Ph.D.
Affiliations: | 2002 | Michigan State University, East Lansing, MI |
Area:
Cell Biology, Genetics, Molecular BiologyGoogle:
"Kim-Hien Dao"Parents
Sign in to add mentor| Justin McCormick | grad student | 2002 | Michigan State | |
| (The role of two Rho GTPases, Cdc42 and Rac1, in the malignant transformation of human fibroblasts.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zhang H, Wilmot B, Bottomly D, et al. (2019) Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood |
| Cortes JE, Wang ES, Watts JM, et al. (2019) Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine Blood. 134: 674-674 |
| Watts JM, Baer MR, Yang J, et al. (2019) Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study Blood. 134: 231-231 |
| Garcia-Manero G, McCloskey J, Griffiths EA, et al. (2019) Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine Blood. 134: 846-846 |
| Dao K, Collins RH, Cortes JE, et al. (2018) Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Blood. 132: 350-350 |
| Watts J, Baer MR, Yang J, et al. (2018) Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Blood. 132: 1453-1453 |
| Daver NG, Kremyanskaya M, O'Connell C, et al. (2018) A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis Blood. 132: 353-353 |
| Dao KT, Tyner JW, Gotlib J. (2017) Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports |
| Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. (2016) Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study Blood. 128: 1949-1949 |
| Mason CC, Khorashad JS, Tantravahi SK, et al. (2014) Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival Blood. 124: 4637-4637 |